173 related articles for article (PubMed ID: 34249954)
21. Cytokine and eosinophil responses in the lung, peripheral blood, and bone marrow compartments in a murine model of allergen-induced airways inflammation.
Ohkawara Y; Lei XF; Stämpfli MR; Marshall JS; Xing Z; Jordana M
Am J Respir Cell Mol Biol; 1997 May; 16(5):510-20. PubMed ID: 9160833
[TBL] [Abstract][Full Text] [Related]
22. Essential thrombocythemia vs. early/prefibrotic myelofibrosis: why does it matter.
Barosi G
Best Pract Res Clin Haematol; 2014 Jun; 27(2):129-40. PubMed ID: 25189724
[TBL] [Abstract][Full Text] [Related]
23. Update from the latest WHO classification of MPNs: a user's manual.
Passamonti F; Maffioli M
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):534-542. PubMed ID: 27913526
[TBL] [Abstract][Full Text] [Related]
24. Myeloid-derived suppressor cells in patients with myeloproliferative neoplasm.
Wang JC; Kundra A; Andrei M; Baptiste S; Chen C; Wong C; Sindhu H
Leuk Res; 2016 Apr; 43():39-43. PubMed ID: 26943702
[TBL] [Abstract][Full Text] [Related]
25. Multiplex bead array assay for detection of 25 soluble cytokines in blister fluid of patients with complex regional pain syndrome type 1.
Heijmans-Antonissen C; Wesseldijk F; Munnikes RJ; Huygen FJ; van der Meijden P; Hop WC; Hooijkaas H; Zijlstra FJ
Mediators Inflamm; 2006; 2006(1):28398. PubMed ID: 16864900
[TBL] [Abstract][Full Text] [Related]
26. Recent advances in understanding myelofibrosis and essential thrombocythemia.
Vainchenker W; Constantinescu SN; Plo I
F1000Res; 2016; 5():. PubMed ID: 27134742
[TBL] [Abstract][Full Text] [Related]
27. GATA1 downregulation in prefibrotic and fibrotic stages of primary myelofibrosis and in the myelofibrotic progression of other myeloproliferative neoplasms.
Sangiorgio VFI; Nam A; Chen Z; Orazi A; Tam W
Leuk Res; 2021 Jan; 100():106495. PubMed ID: 33360878
[TBL] [Abstract][Full Text] [Related]
28. Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms.
Hoermann G; Cerny-Reiterer S; Herrmann H; Blatt K; Bilban M; Gisslinger H; Gisslinger B; Müllauer L; Kralovics R; Mannhalter C; Valent P; Mayerhofer M
FASEB J; 2012 Feb; 26(2):894-906. PubMed ID: 22051730
[TBL] [Abstract][Full Text] [Related]
29. A negative correlation of axial length with aqueous humor concentration of cytokines in patients with congenital cataracts.
Zhang F; Chang P; Zhao Y; Zhao Y
Mol Vis; 2020; 26():91-96. PubMed ID: 32174750
[TBL] [Abstract][Full Text] [Related]
30. The differential diagnosis of classical myeloproliferative neoplasms (MPN): the updated WHO criteria.
Kvasnicka HM
Rinsho Ketsueki; 2019; 60(9):1166-1175. PubMed ID: 31597840
[TBL] [Abstract][Full Text] [Related]
31. Inflammation and myeloproliferative neoplasms.
Lussana F; Rambaldi A
J Autoimmun; 2017 Dec; 85():58-63. PubMed ID: 28669446
[TBL] [Abstract][Full Text] [Related]
32. Gene expression profiling distinguishes prefibrotic from overtly fibrotic myeloproliferative neoplasms and identifies disease subsets with distinct inflammatory signatures.
Wong WJ; Baltay M; Getz A; Fuhrman K; Aster JC; Hasserjian RP; Pozdnyakova O
PLoS One; 2019; 14(5):e0216810. PubMed ID: 31071164
[TBL] [Abstract][Full Text] [Related]
33. Changes in Cytokine Levels in Patients with Severe Fever with Thrombocytopenia Syndrome Virus.
Xu DL; Zhang XM; Tian XY; Wang XJ; Zhao L; Gao MY; Li LF; Zhao JQ; Cao WC; Ding SJ
J Inflamm Res; 2024; 17():211-222. PubMed ID: 38229692
[TBL] [Abstract][Full Text] [Related]
34. Early/prefibrotic primary myelofibrosis in patients who were initially diagnosed with essential thrombocythemia.
Kamiunten A; Shide K; Kameda T; Ito M; Sekine M; Kubuki Y; Hidaka T; Akizuki K; Tahira Y; Toyama T; Kawano N; Marutsuka K; Maeda K; Takeuchi M; Kawano H; Sato S; Ishizaki J; Shimoda H; Yamashita K; Matsuoka H; Shimoda K
Int J Hematol; 2018 Oct; 108(4):411-415. PubMed ID: 29987745
[TBL] [Abstract][Full Text] [Related]
35. Constitutive in vivo cytokine and hematopoietic growth factor gene expression in the bone marrow and peripheral blood of healthy individuals.
Cluitmans FH; Esendam BH; Landegent JE; Willemze R; Falkenburg JH
Blood; 1995 Apr; 85(8):2038-44. PubMed ID: 7718876
[TBL] [Abstract][Full Text] [Related]
36. [The effect of matrix metalloproteinase-9 in granulocyte colony stimulation factor-induced stem cell mobilization].
Jin FY; Qiu LG; Li QC; Meng HX; Wang YF; Yu Z; Li Q; Han JL
Zhonghua Yi Xue Za Zhi; 2006 Nov; 86(42):2966-70. PubMed ID: 17288807
[TBL] [Abstract][Full Text] [Related]
37. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.
Kim SY; Im K; Park SN; Kwon J; Kim JA; Lee DS
Am J Clin Pathol; 2015 May; 143(5):635-44. PubMed ID: 25873496
[TBL] [Abstract][Full Text] [Related]
38. Mesenchymal stem cells in myeloproliferative disorders - focus on primary myelofibrosis.
Selicean SE; Tomuleasa C; Grewal R; Almeida-Porada G; Berindan-Neagoe I
Leuk Lymphoma; 2019 Apr; 60(4):876-885. PubMed ID: 30277128
[TBL] [Abstract][Full Text] [Related]
39. Functional characterization of histamine H4 receptor on human mast cells.
Jemima EA; Prema A; Thangam EB
Mol Immunol; 2014 Nov; 62(1):19-28. PubMed ID: 24934979
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of the bioactive and total transforming growth factor β1 levels in primary myelofibrosis.
Campanelli R; Rosti V; Villani L; Castagno M; Moretti E; Bonetti E; Bergamaschi G; Balduini A; Barosi G; Massa M
Cytokine; 2011 Jan; 53(1):100-6. PubMed ID: 20801055
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
